Blue Shield of California is making changes to lower prescription drug prices by cutting CVS Caremark as its pharmacy benefit manager, partnering with other companies for various services. CEO Paul Markovich predicts that these changes will become the norm in the industry. He believes the current system is problematic, with multiple players in the middle profiting from selling more expensive drugs. Markovich also mentioned that customer satisfaction with CVS Caremark for specialty drugs is high. As for potential FTC action against PBMs, he believes there will be increased scrutiny on healthcare costs overall, but it won’t be limited to one specific player.
Source link
Blue Shield of California CEO on PBM Shakeup: ‘It’s Going to Become the Norm’
